spec sheet11 rows
WAY-200070 is a synthetic nonsteroidal agonist of estrogen receptor beta, made at Wyeth as one of a series designed to tell the two estrogen receptors apart [5]. It binds ERbeta in the low nanomolar range and ERalpha roughly two orders of magnitude more weakly, which is exactly what makes it useful: an effect that appears with WAY-200070 and vanishes in an ERbeta knockout mouse belongs to that receptor rather than to estrogen in general, and that control was actually run [6]. Its reputation in neuroscience comes from hippocampal work, where ERbeta activation raised synaptic proteins and improved memory in rodents [1]. Outside the brain the same compound has been used to study asthma, kidney fibrosis, insulin secretion and cancer cell growth. It is a laboratory probe throughout; there is no approved human use, no human trial, and no human safety data of any kind.
- Enhances hippocampal synaptic plasticity and memory in preclinical models
- Selective activation of estrogen receptor beta for clean mechanistic studies
- Neuroprotective in some neuronal injury models
- Effects on learning can be dose- and task-dependent
- Increased agonistic behaviour in gonadally intact mice, including aggressive grooming and pushing down an intruder
- Altered anxiety related behaviour in zebrafish larvae, and altered basal activity at supraphysiological concentrations with no added estradiol
- Learning effects that reverse direction with dose and task rather than improving across the board
- Intrinsic endocrine activity in pancreas, kidney, airway and reproductive tissue, none of it characterised in a person
- Blunted noradrenergic stress gene responses in rats, an effect on stress physiology rather than a neutral one
- No human safety data of any kind, so there is no known adverse effect profile to compare against
Overview
WAY-200070 was characterized as a benzoxazole ERbeta-preferring agonist that allowed researchers to activate ERbeta selectively without the confounding alpha-mediated effects of estradiol. Its most influential CNS finding is that ERbeta activation regulates hippocampal synaptic plasticity and improves memory, establishing ERbeta as a distinct cognitive target within estrogen signaling [1].
Subsequent electrophysiological work showed that an ERbeta agonist rapidly potentiates glutamatergic synaptic transmission in the hippocampus, and did so through postsynaptic mechanisms in males, illustrating sex-specific receptor contributions [2]. WAY-200070 has also been used to demonstrate ERbeta-dependent neuroprotection of motor neurons, an effect that can be amplified by neuroprotective microRNAs [3]. Beyond the nervous system it is a standard ERbeta agonist in studies of airway remodeling, metabolism, and reproductive biology, where it helps isolate the beta subtype's actions [4].
Because ERbeta agonism carries endocrine consequences and WAY-200070 has never been developed for human use, it should be regarded strictly as a laboratory tool. Its relevance to nootropics is conceptual, centering on the role of ERbeta in hippocampal function rather than on any demonstrated human benefit.
- The landmark study using WAY-200070 helped show that estrogen's benefits for memory can run through the beta receptor, not only the alpha receptor.
- The same compound is used far outside neuroscience, including in asthma airway remodeling and metabolism research.
Mechanism
WAY-200070 is 7-bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol, one of a series of aryl diphenolic azoles designed at Wyeth around a single conservative residue difference between the two receptor binding pockets, methionine in ERalpha against isoleucine in ERbeta; the 7-substituted benzoxazoles came out as the most selective ligands of the series [5]. In radioligand displacement of tritiated 17beta-estradiol against receptors expressed in E. coli, the values deposited in ChEMBL from that paper put it near 2 nM on human ERbeta against roughly 155 nM on human ERalpha, about 78 fold; rat ERbeta near 1.2 nM against 132 nM at rat ERalpha, about 109 fold; mouse ERbeta near 1.7 nM against 132 nM at mouse ERalpha [5]. That ratio is the entire product.
Target engagement was demonstrated rather than inferred. In male mice a single subcutaneous dose moved striatal ERbeta out of the cytosol into the nucleus within fifteen minutes and raised c-fos by four hours, and neither effect appeared in ERbeta knockout animals [6]. Downstream, striatal rose by about half and stayed up from ninety minutes to four hours while roughly doubled transiently, and both changes were absent in the knockouts [6].
In the , ERbeta activation raised PSD-95, synaptophysin and the subunit GluR1 in vivo, again with the effects absent in ERbeta knockout mice [1]. In cultured cortical neurons the same increased spine density and membrane PSD-95 and phosphorylated PAK and ERK1/2, which points at regulation of the actin cytoskeleton as the proximal step [9]. That reading is supported from the other direction: the acute facilitation of long term potentiation produced by or a beta selective in adult hippocampal slices was completely eliminated by latrunculin, which prevents actin filament assembly [8]. The acute potentiation is not one mechanism in both sexes, since presynaptic and postsynaptic contributions differ between male and female rats [2]. Protection of hippocampal CA1 neurons against ischaemic death can run through either receptor subtype rather than through beta alone [10], and ERbeta agonists are also neuroprotective in motoneuron injury models, an effect that neuroprotective microRNAs amplify [11][3].
Outside the brain the same receptor does different work and this compound is how much of it was shown. In human airway smooth muscle it suppressed extracellular matrix deposition by damping NF-kappaB and AP-1 activity, where the ERalpha in the same experiment did not [20]. In mouse kidney it attenuated fibrosis by suppressing the transcriptional activity of Smad3 [22]. In mouse and human islets it enhanced glucose stimulated secretion [18], and signalling through all three estrogen receptors drives proglucagon derived release from alpha and L cells [19]. In ovarian and triple-negative breast cancer lines it reduced proliferation and invasion at nanomolar concentrations [24][25].
receptor fingerprint
receptor beta (ERbeta)Selective agonist; the defining and primary activity
receptor alpha (ERalpha)Weak agonist; it does bind alpha, roughly two orders of magnitude more weakly
Hippocampal plasticityEnhancement; raises PSD-95, synaptophysin and GluR1 in vivo and facilitates long term potentiation in slices
Cortical dendritic spinesIncreases spine density and membrane PSD-95; phosphorylates PAK and ERK1/2
Striatal and Delayed rise after a single subcutaneous dose in male mice; absent in ERbeta knockouts
NF-kappaB and AP-1 signalling in airway smooth muscleSuppression; the ERalpha agonist did not do this in the same experiment
Pancreatic beta cell secretionEnhancement of glucose stimulated insulin release
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
There is no human safety data for WAY-200070 of any kind. It has never been given to a person in a published study, there is no approved use anywhere, and no toxicology programme has been reported. Everything below comes from animals and cells.
The classic estrogenic endpoints look quiet, which was the point of the programme. Most of the agonists in this series that were at least roughly fifty fold selective for ERbeta were inactive in uterotrophic, osteopenia and vasomotor instability models while remaining active in a rat model of inflammatory bowel disease [5]. Compound specific confirmation exists: in ovariectomized rats given three weeks of daily injections, estradiol benzoate and the ERalpha agonist both reduced body weight and increased uterine weight while WAY-200070 did neither [15]. In quail embryos exposed in ovo, the ERalpha agonist feminized testes and malformed the Mullerian ducts and the ERbeta agonist produced none of those effects and did not modify the ERalpha agonist's action [26].
Quiet on those endpoints is not the same as inert. Behaviour moves. The compound increased agonistic behaviours such as aggressive grooming and pushing down an intruder in gonadally intact mice [12], altered light and dark choice behaviour in zebrafish larvae along with hypothalamic crh expression [16], and altered basal activity in larval zebrafish at supraphysiological concentrations even with no added estradiol [17]. Social behaviour is affected too, with alpha and beta selective agonists producing different effects on social learning of food preferences in female mice [7]. Cognition moves in both directions rather than upward: estrogen receptor selective agonists shifted learning in female rats in a dose specific and task specific way, favouring hippocampus sensitive performance under some conditions and impairing striatum sensitive performance under others [4]. Stress physiology is affected unevenly, with the compound blocking a noradrenergic gene response to a single immobilization but not to repeated immobilization [15]. It is antinociceptive in a rat visceral pain model, which is a pharmacological effect on pain processing rather than a neutral one [14].
The receptor itself is not confined to the brain. It governs insulin secretion and beta cell mass in rodents [18], proglucagon derived peptide release [19], airway remodelling and hyperreactivity [21], renal fibrosis [22] and proliferation in hormone sensitive cancer lines [24][25]. Loss of ERbeta in female mice produces an excitatory and inhibitory synaptic imbalance that drives temporal lobe epilepsy, which places this receptor inside seizure biology and means pushing it hard is not an obviously neutral act [23].
None of that constitutes a safety profile. It describes a compound with real activity across several organ systems and no study that has ever asked what a dose does to a person. Treat it as laboratory material. Not medical advice.
History
WAY-200070 came out of a Wyeth medicinal chemistry programme in the early 2000s aimed at subtype selective estrogen receptor ligands, reported in 2004 alongside its more selective sibling ERB-041 [5]. The rationale at the time was therapeutic rather than cognitive: ERbeta selective agonists looked like a way to treat inflammatory conditions such as inflammatory bowel disease, rheumatoid arthritis, endometriosis and sepsis without triggering the classic estrogenic effects, and the preclinical case for that was set out shortly afterwards [13].
Its lasting influence came from a different direction. The 2008 demonstration that estrogen receptor beta regulates hippocampal synaptic plasticity and improves memory came out of the same laboratory and rested on selective ERbeta agonists paired with knockout mice [1], and a companion paper the same year made it the first ERbeta agonist characterised as a candidate anxiolytic and antidepressant, complete with knockout controls [6]. It never entered human development; ERB-041 was the sibling that went further.
Since then it has spread sideways into fields the original programme was not aimed at, including motoneuron neuroprotection [11][3], visceral pain [14], asthma and airway remodelling [20][21], kidney fibrosis [22], diabetes and islet biology [18][19], oncology [24][25], epilepsy [23] and comparative endocrinology in birds and fish [26][16][17]. It appears in the literature under two names, WAY-200070 and Br-ERb-041, and the second is worth knowing because a search on the codename alone misses papers that used it [4].
Reputation
Among researchers WAY-200070 is a standard reagent rather than a drug candidate: the thing to reach for when a study needs estrogen receptor beta pressed without alpha coming along, usually run beside a second beta agonist such as diarylpropionitrile or ERB-041 so a result does not rest on one chemical [14][24]. That is a modest reputation and an accurate one.
It has essentially no history as a consumer nootropic and has never been sold as a supplement, though at least one research chemical vendor now lists it, which is a much newer development than its literature. Where it does carry a cognitive reputation, that reputation is borrowed rather than earned: it rests on what the hippocampal and cortical work says about the receptor [1][9], not on anything measured in a person. Its second and less discussed reputation is as an endocrine and anti-inflammatory tool across airway, kidney, pancreas and oncology work, where the interest is in the receptor's peripheral biology and nobody is thinking about memory at all [20][22][18][24].
Resources
This entry is here for reference.
Research
- 2004first citedDesign and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta l…
- 2016most active year4 papers
- 2024most recentModeling Sex-Bias in Anxiety: Pros and Cons of a Larval Zebrafish Model.
- 1.Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory.
- 2.17β-Estradiol Acutely Potentiates Glutamatergic Synaptic Transmission in the Hippocampus through Distinct Mechanisms in Males and Females.
- 3.Experimental Procedures for Demonstration of MicroRNA Mediated Enhancement of Functional Neuroprotective Effects of Estrogen Receptor Agonists.
- 4.Estrogen Receptor-Selective Agonists Modulate Learning in Female Rats in a Dose- and Task-Specific Manner.
- 5.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
- 6.WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent.
- 7.Differential effects of estrogen receptor alpha and beta specific agonists on social learning of food preferences in female mice.
- 8.Cytoskeletal changes underlie estrogen's acute effects on synaptic transmission and plasticity.
- 9.Estrogen receptor ß activity modulates synaptic signaling and structure.
- 10.Estrogen can act via estrogen receptor alpha and beta to protect hippocampal neurons against global ischemia-induced cell death.
- 11.MiR-7-1 potentiated estrogen receptor agonists for functional neuroprotection in VSC4.1 motoneurons.
- 12.Agonistic behavior in males and females: effects of an estrogen receptor beta agonist in gonadectomized and gonadally intact mice.
26 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is WAY-200070 an estrogen?
It is not estradiol, but it is a selective agonist of the estrogen receptor beta subtype, so it activates part of the estrogen signaling system.
Why is it used in memory research?
It selectively activates ERbeta, which studies show enhances hippocampal plasticity and memory, helping researchers separate ERbeta effects from ERalpha effects.
Can people take it for cognition?
No. It is an experimental research chemical with endocrine activity and no human safety data or approved use.
Why do so many memory papers use it?
Because it answers a question estradiol cannot. Estradiol hits both receptors, so an effect on the hippocampus cannot be assigned to one of them. A beta selective agonist can be paired with an ERbeta knockout mouse, and if the effect disappears in the knockout it belonged to that receptor. That is exactly how the hippocampal plasticity and memory result was established [1], and the same knockout control confirmed target engagement in the neurochemistry work [6].
Can I take it to improve my memory?
No, and the reason is not caution for its own sake. Nothing has been measured in a person: no published human dose, no human pharmacokinetic study, no human safety data. The rodent cognitive record is also not uniformly positive, since estrogen receptor selective agonists shifted learning in female rats in a dose specific and task specific way, favouring hippocampus sensitive performance in some conditions and impairing striatum sensitive performance in others [4].
Does it cause estrogenic side effects like estradiol does?
In animals, the classic ones stayed quiet. Most compounds in this series that were at least roughly fifty fold beta selective were inactive in uterotrophic, osteopenia and vasomotor models [5], and three weeks of daily injections in ovariectomized rats produced neither the weight loss nor the uterine growth seen with estradiol benzoate or an ERalpha agonist [15]. That is not the same as being inert. Estrogen receptor beta is active in the pancreas [18], the airway [20], the kidney [22] and the brain's excitatory and inhibitory balance [23], and none of those has been checked in a person taking this compound.
Is it the same thing as ERB-041 or DPN?
No, though they are used for the same job. ERB-041 came from the same Wyeth series and is more beta selective still [5]; DPN, diarylpropionitrile, is a structurally unrelated ERbeta agonist. Papers often run two of them side by side precisely so a result does not rest on one chemical [14][24]. Worth knowing separately: WAY-200070 appears in the literature under a second name, Br-ERb-041, so a search on the codename alone misses papers that used it [4].
Why is a laboratory reagent being sold at all?
It was never developed into a medicine, so it is not a prescription product, and vendors list it as laboratory material. That labelling happens to be accurate here in a way it often is not: this really is a tool compound, its entire record is preclinical, and the people who generated that record were measuring receptor biology rather than looking for something to take.
Limitations of the evidence
- Intrinsic endocrine (estrogenic) activity with unknown human effects
- No human safety data
- No human has ever received this compound in a published study, so every statement about it is preclinical.
- No pharmacokinetic data exists in any species and no metabolite has been identified, so nothing anchors a dose, an interval or a duration.
- The cognitive effects are not uniformly positive; the same agonist class improved hippocampus sensitive learning and impaired striatum sensitive learning depending on dose and task.
- Much of the record is comparative rather than compound specific, with the effect attributed to estrogen receptor beta as a class and this molecule used as one of several probes.
- A large share of the literature sits in fish, birds and reptiles, where estrogen receptor biology differs from mammals and results should not be read across.
- ChEMBL also records an HDAC6 IC50 near 854 nM from a 2021 screening deposition with no journal and no PubMed record, so the selectivity claim is a claim about estrogen receptors and not about the whole proteome.
Adverse effects
- Effects on learning can be dose- and task-dependent
- Increased agonistic behaviour in gonadally intact mice, including aggressive grooming and pushing down an intruder
- Altered anxiety related behaviour in zebrafish larvae, and altered basal activity at supraphysiological concentrations with no added estradiol
- Learning effects that reverse direction with dose and task rather than improving across the board
- Intrinsic endocrine activity in pancreas, kidney, airway and reproductive tissue, none of it characterised in a person
- Blunted noradrenergic stress gene responses in rats, an effect on stress physiology rather than a neutral one
- No human safety data of any kind, so there is no known adverse effect profile to compare against
Notes and cautions
- Indexed under two names: WAY-200070 and Br-ERb-041. PubMed maps both to the same Supplementary Concept, and the codename alone misses papers.
- Origin paper is Malamas 2004 in J Med Chem, which is also the source of every affinity value in ChEMBL for this compound.
- ChEMBL records an HDAC6 IC50 near 854 nM from a 2021 screening deposition that carries no journal and no PubMed record; it is the only off-target signal of any size in the compound's ChEMBL entry and it is reported here rather than in the prose for that reason.
- Sold by at least one research chemical vendor as a liquid, labelled for laboratory use only.